OCT 2 9 2002 E

PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : See Attached Exhibit "A" )
App. No. : 09/885, 72/ )

Filed : See Attached Exhibit "A" (920/0)

For : See Attached Exhibit "A"

RECEIVED

OCT 3 1 2002

TECH CENTER 1600/2900

#10. 1993 111402.

# ESTABLISHMENT OF RIGHT OF ASSIGNEE TO TAKE ACTION AND

REVOCATION AND POWER OF ATTORNEY

#### WITH CHANGE OF ADDRESS

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The undersigned is empowered to act on behalf of the assignee below (the "Assignee"). The original assignments from the inventors to Ashni Naturaceuticals, Inc. ("Ashni") are recorded at the Reel and Frame numbers set forth on attached Exhibit "A" or, in the case of Assignments not yet recorded in the PTO, as reflected in the copies of said Assignment which are attached to Exhibit "A." As evidenced in the attached "Confirmation of Assignment of Patent Applications From Ashni Naturaceuticals, Inc. to MetaProteomics, LLC" (Exhibit "B"), the title to the intellectual property owned by Ashni, as identified on Exhibit "A" hereto, was vested in MetaProteomics, LLC, Inc. by way of a Joint Venture Agreement executed on June 14, 2002 and effective as of March 16, 2002. These documents represent the entire chain of title for these inventions from the Inventors to the Assignee.

I declare that all statements made herein are true, and that all statements made upon information and belief are believed to be true, and further, that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or

App. No.

Filed

See Attached Exhibit "A"

imprisonment, or both, under 18 U.S.C. § 1001, and that willful, false statements may jeopardize the validity of the applications, or any patents issuing thereon.

The undersigned hereby revokes any previous powers of attorney in the subject application, and hereby appoints the registrants of Knobbe, Martens, Olson & Bear, LLP, Customer No. 20,995, as its attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected herewith. This appointment is to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71.

Please use Customer No. 20,995 for all communications.

METAPROTEOMICS, LLC

Dated: 1011107 ·

Title:

Address: 100 Avenida La Pata

San Clemente, CA 92673

CCT-3121,DOC:eb

#### **RECEIVED**



## EXHIBIT "A"

OCT 3 1 2002

# PATENT APPLICATIONS ASSIGNED FROM ASHNI NATURACEUTICALS, INC. TO METAPROTEOMICS, LLC

TECH CENTER 1600/2900

Atty. Docket #	Serial No.	Filed	Title Assignment Recorded		Reel	Frame
ASHMET.001A	09/885,721	6/20/01	Complex Mixtures			
			Exhibiting Selective	3/8/02	012695	0107
			Inhibition of			
			Cyclooxygenase-2	se-2		
ASHMET.002A1	09/919,349	7/31/01	Composition of	1/4/02 012429		0073
,			Sesquiterpene			
			Lactones and			
			Kitepene Triepoxide			·
			Lactones For	·		į
			Synergistic Inhibition			
ASHMET.004A	09/920,339	8/1/01	Composition of	1/4/02	012431	0401
ľ			Diterpene Triepoxide	(See * herein)	(See * herein)	(See * herein)
l.			Lactones and	*Assignment l	being re-record	
			Ditepene Lactones or	there was a ty	pographical er	ror in the
			Triterpenes for		r on the Assign	
	İ		Synergistic Inhibition	Recordation (	Cover Sheet. <u>C</u>	Copy attached
			of Cyclooxygenase-2			
ASHMET.005A	10/198,277	7/16/02	Curcuminoid	7/16/02	013121	0140
			Compositions			·
			Exhibiting			
			Synergistic Inhibition			
			of the Expression			
	•		and/or Activity of			
			Cyclooxygenase-2			
ASHMET.006A	10,234,002	8/29/02	Arginine	Assignment s	ent to PTO for	recordation
			Compositions for	on 8/29/02. C		
			Coordinate			
			Modification of			
			Multiple			
·			Cardiovascular Risk			
			Factors			
ASHMET.010CP1	10/109,954	3/29/02	Combinations of	3/29/02	012,749	0401
			Psyllium and		,	
			Chitosan for			
į			Synergistic			
			Adsorption of			
			Triglyceride			

OCT-18-2002 16:42

801 983 0342 P.02/02

9303



EXHIBIT B

RECEIVED

OUT 3 1 2002

CONFIRMATION OF ASSIGNMENT OF PATENT APPLICATIONS FROM
ASHNI NATURACEUTICALS, INC. TO TEC

METAPROTEOMICS, LLC

TECH CENTER 1600/2900

		0	
I. DINESH	C	TATEL	, declare as follows:

- 1. I am the <u>Circulation</u>, <u>less</u>) of Ashni Naturaceuticals, Inc., a Delaware corporation ("Ashni'), which is one of the partners of MetaProteomics, LLC, a Callfornia Limited Liability Company ("MetaProteomics");
- 2. Pursuant to a separate document entitled "Joint Venture Agreement," effective as of March 16, 2002, Ashni Naturaceuticals, Inc. assigned to MetaProteomics all of its right, title and interest in the patent applications listed in Exhibit "A" attached hereto and incorporated herein by reference; and

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct and this Declaration was executed this 1811 day of October 2002, at Salt lake City. Utal.

Signature

Printed Named: DINESH C PATEL

CCT-1116.DOC:eb

COPY

TOTAL P.02

### **RECEIVED**

OCI 3 1 2002





# EXHIBIT "A" PATENT APPLICATIONS ASSIGNED FROM ASHNI NATURACEUTICALS, INC. TO METAPROTEOMICS, LLC

Atty. Docket #	Serial No.	Filed	Title
ASHMET.001A	09/885,721	6/20/01	Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2
ASHMET.002A1	09/919,349	7/31/01	Composition of Sesquiterpene Lactones and Kitepene Triepoxide Lactones For Synergistic Inhibition
ASHMET.004A	09/920,339	8/1/01	Composition of Diterpene Triepoxide Lactones and Ditepene Lactones or Triterpenes for Synergistic Inhibition of Cyclooxygenase-2
ASHMET.005A	10/198,277	7/16/02	Curcuminoid Compositions Exhibiting Synergistic Inhibition of the Expression and/or Activity of Cyclooxygenase-2
ASHMET.006A	10,234,002	8/29/02	Arginine Compositions for Coordinate Modification of Multiple Cardiovascular Risk Factors
ASHMET.010CP1	10/109,954	3/29/02	Combinations of Psyllium and Chitosan for Synergistic Adsorption of Triglyceride